CD19 and non-Hodgkin lymphoma: Second-generation anti-CD19 CAR-T cells showed strong antitumor efficacy in patients with B cell ALL and NHL and were formulated to contain one endodomain of a stimulation epitope, such as CD28 or 4-1BB [4–6].